Breast cancer

• 1. Introduction

  ›

  Breast cancer is the most common invasive cancer in women across most of the world, accounting for 25% of all cancer cases in women globally. In 2018 alone, it produced two million new diagnoses and 627,000 deaths. Yet the oldest known evidence of this disease reaches back 4,200 years, to an ancient Egyptian woman whose remains from the necropolis of Qubbet el-Hawa bear the distinctive damage of metastatic spread. The Edwin Smith Papyrus, which describes eight cases of breast tumors, closes with a verdict that haunted medicine for centuries: "There is no treatment." How did humanity move from that sentence of hopelessness to five-year survival rates exceeding 90% in many countries? And why, despite those gains, do Black women in the United States remain more likely to die of this disease than white women at every age? Those questions sit at the heart of this documentary.

• 2. How the Body Goes Wrong

  ›

  Estrogen, the hormone that drives breast development through puberty, menstrual cycles, and pregnancy, also plays a central role in driving breast cancer. The hormone activates cell growth, and the imbalance between estrogen and progesterone during menstrual phases can trigger cell proliferation. Oxidative metabolites of estrogen can accumulate DNA damage, and repeated cycling, if the repair process is impaired, can transform a normal cell into a pre-malignant one and eventually a malignant one.

  Normal cells carry built-in instructions to stop dividing and to self-destruct when they are no longer needed. Two protective pathways, the PI3K/AKT pathway and the RAS/MEK/ERK pathway, shield cells from premature death. When mutations permanently switch these pathways to the "on" position, a cell loses its ability to self-destruct. In some breast cancers, the gene for the PTEN protein is mutated, locking the PI3K/AKT pathway open so the cancer cell survives indefinitely.

  About 70% of breast cancer patients carry hormone receptor-positive, ERBB2-negative tumors. About 15% of cases are triple-negative, meaning the tumor lacks all three of the conventional molecular markers. Triple-negative disease is more common in younger Black and Hispanic women, a fact that carries significant implications for both prognosis and treatment options. GATA-3, a gene that directly controls estrogen receptor expression and epithelial differentiation, is associated with poor prognosis when lost, because cancer cells become more invasive and prone to spreading.

• 3. Identifying the Disease

  ›

  Most people with breast cancer have no symptoms at the time of diagnosis; a screening test finds their tumor. For those who do notice something, a new lump is the most common sign, though the majority of breast lumps turn out not to be cancerous. Inflammatory breast cancer, which affects up to 5% of people with the disease, follows a different course: cancer cells block the lymph vessels, causing one breast to swell substantially and redden over three to six months. Paget's disease of the breast, affecting up to 3% of cases, produces an eczema-like irritation on the nipple and areola.

  The standard screening tool is mammography, which presses each breast between two plates and captures a low-dose X-ray image. Radiologists score results using the six-point Breast Imaging-Reporting and Data System (BI-RADS), the most widely used scale globally. Mammography can detect around 90% of tumors in the least dense breast tissue, but only about 60% in the most dense tissue. Women with particularly dense breasts can be screened instead by ultrasound, MRI, or tomosynthesis, all of which detect tumors more sensitively. Regular screening mammography reduces breast cancer deaths by at least 20%, though the procedure misses about 1 in 8 cancers overall.

  When imaging suggests a suspicious mass, a biopsy confirms or rules out cancer. Core needle biopsy, using a hollow needle to collect tissue, is the typical method. Around 10-20% of breast biopsies come back positive for cancer. The remainder reveal fibrocystic breast changes, a term covering benign fluid pockets, cell growth, or fibrous tissue. Once cancer is confirmed, pathologists assess the tumor's grade, its receptor status for estrogen, progesterone, and HER2, and its stage using the TNM system, which scores the tumor size and extent, lymph node involvement, and whether metastases have been detected.

• 4. The Weight of History

  ›

  For much of recorded history, breast cancer was understood through humoralism, the ancient framework that attributed disease to imbalances in the body's fundamental fluids. Physicians from the classical world through the 17th century most often concluded that breast cancer arose from an excess of black bile, or alternatively that it was a form of divine punishment. Surgery was theoretically possible, but the risks were severe. The surgeon Richard Wiseman documented in the mid-17th century that of 12 mastectomies he observed, two patients died during the operation and eight more died shortly after from progressive cancer. Only two survived.

  Mastectomy had in fact been proposed as early as AD 548, when the court physician Aetios of Amida recommended it to Theodora. French surgeon Jean Louis Petit took the procedure further in the early 18th century by removing the axillary lymph nodes during total mastectomy, recognizing that doing so reduced recurrence. His approach built on the prior work of Bernard Peyrilhe, who in the 17th century also removed the underlying pectoral muscle to improve the prognosis. But without anesthesia or antiseptics, mastectomy remained a painful and dangerous ordeal, and many physicians remained skeptical of surgery.

  When in 1664 Anne of Austria was diagnosed with breast cancer, her initial treatment was compresses soaked in hemlock juice. When her lumps grew, the King's physician moved to arsenic ointments. She died in 1666 in what the historical record describes as atrocious pain. Breast cancer stayed relatively uncommon until the 19th century, when improved sanitation and the control of infectious diseases extended lifespans long enough for the disease to develop. William Stewart Halsted began performing radical mastectomies in 1882, and those surgeries, before the age of 90% survival rates, had raised 20-year survival from just 10% to 50%.

• 5. Treating the Disease Today

  ›

  Surgery remains the foundation of local breast cancer treatment. When tumors have not spread beyond the breast, surgeons aim to spare as much healthy tissue as possible, removing just the tumor (lumpectomy) or a larger portion (partial mastectomy). Less than 5% of those who receive surgery and radiation therapy see their breast tumor return. After surgery and radiation, chemotherapy reduces the risk of cancer recurring over the following decade by around a third, though 1-2% of those on chemotherapy experience life-threatening or permanent side effects.

  For the roughly 15-20% of tumors that are HER2-positive, adding the targeted antibody trastuzumab to chemotherapy reduces the risk of recurrence and death by at least a third. Trastuzumab is given weekly or every three weeks for twelve months. Combining it with a second HER2-targeted antibody, pertuzumab, slightly improves outcomes further.

  For hormone receptor-positive tumors, endocrine therapy follows chemotherapy. Tamoxifen, which blocks the estrogen receptor in breast tissue, reduces the risk of breast cancer death by around 40% over ten years. Endocrine therapy is typically recommended for at least five years after surgery, and sometimes continued for ten years or longer. For those with metastatic disease, the bones are the most common site of spread at 67% of cases, followed by the liver at 41%, lungs at 37%, brain at 13%, and peritoneum at 10%. Treatment in metastatic disease shifts focus toward extending quality of life, cycling through chemotherapy agents as each one loses effectiveness. A drug called imlunestrant, marketed as Inluriyo, received approval in the United States in September 2025 for use in this setting.

• 6. Risk, Prevention, and Genetics

  ›

  Up to 80% of the variation in breast cancer frequency across countries traces to differences in reproductive history. Women who begin menstruating before age 12, or who undergo menopause after age 51, carry increased risk. Giving birth in adolescence, by contrast, reduces risk by around 70% compared to women who never have children. That protection fades with each passing year of maternal age and disappears entirely by age 35. Every 12 months of breastfeeding reduces risk by approximately 4%.

  Alcohol is among the most common modifiable risk factors. Globally, about one in ten breast cancer cases is attributed to alcohol consumption, with risk beginning even at less than half of one drink per day. A high body mass index accounts for 7% of breast cancers; diabetes mellitus is responsible for an additional 2%. Long-term smokers face a relative risk increase of 35-50%. Physical inactivity is linked to about 10% of cases, and combined lifestyle changes could theoretically prevent almost a quarter of worldwide breast cancer cases, though the remaining three-quarters cannot be prevented through lifestyle modifications.

  For those with inherited genetic variants, the risk profile changes dramatically. Women with pathogenic variants in BRCA1 or BRCA2 face around a 70% lifetime chance of developing breast cancer and an approximately 33% chance of developing ovarian cancer. Variants in PALB2 carry about a 50% increased breast cancer risk. For women at normal risk, preventive mastectomy offers no survival benefit. For those with faulty BRCA1 or BRCA2 genes, it reduces risk of developing breast cancer by more than 95%. The average wait time for such preventive procedures, however, is two years, considerably longer than what most medical guidelines recommend.

• 7. Who Bears the Burden

  ›

  Breast cancer is more than 100 times more common in women than in men. For transgender women on gender-affirming hormone therapy, breast cancer is 46 times more common than in cisgender men. Rates of the disease generally correlate with wealth: roughly 1 in 12 women in wealthier countries receive a breast cancer diagnosis over their lifetimes, compared to 1 in 27 in lower-income countries. Yet death rates tell a more complicated story. In wealthy countries, 1 in 71 women die of the disease; in lower-income countries, 1 in 48 die, partly because screening and treatment remain harder to access.

  Within the United States, the disparities run along racial lines with particular sharpness. Black women at every age are more likely to die of breast cancer than white women, despite breast cancer incidence among Black women aged 45 and older being higher than in white women of the same age group. The median age of breast cancer diagnosis for Black women is 59, compared to 62 for white women. The five-year survival rate is 81% in Black women and 92% in white women. Incidence in Black women has increased by 0.4% per year since 1975.

  Clinical trials have reinforced rather than resolved these gaps. Less than 3% of participants in US clinical trials identify as Black, even though Black Americans represent 12.7% of the national population. Hispanic and indigenous women are also significantly underrepresented. Lengthy participation without financial compensation discourages low-income women who cannot miss work or afford travel costs. Community outreach through patient navigators, mobile screening vehicles, and legislation mandating insurance coverage of mammograms have each shown measurable success in narrowing screening gaps, particularly in ethnic minority communities.

• 8. A Culture Built Around a Ribbon

  ›

  Before the 20th century, breast cancer was discussed in hushed tones, treated as something shameful rather than a medical condition. The first organized public campaign was the "Women's Field Army," run by the American Society for the Control of Cancer during the 1930s and 1940s. In 1952, a peer-to-peer support program called "Reach to Recovery" began sending women who had survived mastectomy into hospitals to visit newly diagnosed patients.

  The pink ribbon became the disease's defining symbol in the 1990s, when US corporations launched cause-related marketing campaigns donating to breast cancer initiatives for each pink ribbon product sold. The Wall Street Journal observed that the strong emotions provoked by breast cancer translate to a company's bottom line. Critics argued that the arrangement created a form of slacktivism, distracted attention from the lack of progress on prevention and cure, and sometimes involved companies selling products that themselves increase breast cancer risk. Breast Cancer Action launched the "Think Before You Pink" campaign in 2002, targeting businesses that used the pink ribbon to market alcohol and other products linked to higher breast cancer risk.

  Writers took aim at the culture surrounding the ribbon as well. In her 2006 book "Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy," Samantha King argued that breast cancer had been transformed from a disease into a market-driven industry of survivorship. Barbara Ehrenreich, writing in Harper's Magazine in 2010, observed that breast cancer culture casts treatment as a rite of passage rather than an illness, pressuring patients to normalize their appearance and suppress anger and sadness. The first breast cancer cell line, BT-20, was established in 1958, and the cell lines that followed have underpinned decades of laboratory research; yet the four lines MCF-7, T-47D, MDA-MB-231, and SK-BR-3 account for more than two-thirds of all studies on breast cancer cell lines, a concentration that researchers have flagged as a constraint on the field's breadth.